drugset / Trial / NCT07610837

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

NCT07610837

Phase 2 Recruiting 104 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.

Timeline

Start
2026-05-07
Primary completion
2027-07-07
Completion
2027-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2389 Small molecule Oral